NTRK1 and lung carcinoma: Additionally, the discovery of lung cancer driver genes and their targeted inhibitors, such as epidermal growth factor receptor (EGFR) and ALK receptor tyrosine kinase inhibitors, has achieved remarkable clinical benefits45,46.